University of Iowa Hospitals and Clinics

Clinical Trial Details

Short Title
Seraphin
Official Title

Study of the SERAPHIN in Patients With Symptomatic Pulmonary Arterial Hypertension

Description

Long-term Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension (SERAPHIN OL)

The main objective of the AC 055 303/SERAPHIN OL study, which will follow the AC 055 302/SERAPHIN study, will be to assess the long-term safety and tolerability of ACT 064992 in patients with symptomatic PAH.

 

This study is closed to enrollment and in the follow-up phases.

 

Please refer to www.clinicaltrials.gov identifier NCT00667823 for more information

Start Date
July 1, 2008
End Date
November 30, 2014
Gender Preference
None
Age Group
18 - 99 years
Principal Investigator
Sif Hansdottir, MD
Contact Info

Pulmonary Hypertension Study

Page Scovel, RN

phone:  319-356-1028

fax:  319-356-7087

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.